Founded in 2003 as a spin out from Millennium Pharmaceuticals’ Structure- based discovery department, Sareum Holding plc is engaged in discovery and development of innovative drugs with aim to improve the treatment of cancer, autoimmune diseases, and other serious medical conditions where current therapies are not sufficient. In October 2004, the company got listed to the Alternative Investment Market (AIM) segment of the London Stock Exchange and with an outsourced and collaborative business model. Since 2008, Sareum shifted its focus on developing its drug discovery programmes.
The company’s objective is to enhance the value through licensing its candidates at the preclinical or early clinical trial stage to the global leading pharmaceutical and biotechnology companies and this is achieved by maintaining low cost by engaging in research and development collaboration and having a small in-house team, having access to global network of research experts to progress programmes, to reduce risk and increase potential success rate it conducts multiple drug development programmes and pursuing laboratory-based research using external providers, currently the two collaborative partners are SRI International which work on TYK2/JAK1 (Autoimmune) programme and Chinese Specialty Pharma which work on FLT3+Aurora with the company.
The company’s four development programmes: Chk1 Kinase, TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer and Aurora+FLT3 Kinase. Chechpoint Kinase 1 (Chk1) program is the most advance programme that shows strong potency in multiple cancer models, with its partners Institute of Cancer Research and the CRT Pioneer fund, it has cleared the second of two phase 2 clinical trial and then in 2016 it was licensed to Sierra Oncology Inc which responsible for further clinical. TYK2 and JAK1 are in preclinical development stage and is the member of the Janus Kinase family of protein Kinase enzymes, which promote inflammatory response in autoimmune diseases, maintain strong immune system, respiratory infection and tumour cell accretion in certain cancer. Cancer- TYK2/JAK1 Kinases is in the preclinical development stage which can treat psoriasis rheumatoid arthritis, inflammatory diseases and lupus by maintaining the strong immune system. Cancer- FLT3+Aurora Kinases is in the preclinical development stage and aims to treat the Acute Myeloid Leukaemia (AML) and other blood cancers. Further, the company’s other programmes includes VEGFR-3 Kinase, Fatty Acid Synthase- FASN, ALK Kinase, FLT3 Kinase and Microtubule Binding Agents. The company is also engaged in research and development of the potential of its TYK2/JAK1 programmes to treat the covid-19 patients and other lung diseases.
Unit 2A Langford Arch, London Road, Pampisford CB22 3FX United Kingdom